The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial virus, or RSV, a common but potentially serious seasonal illness.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a recently published study.